Svennerholm Ann-Mari, Lundgren Anna
Department of Microbiology and Immunology, Institute of Biomedicine, Göteborg University, Göteborg, Sweden.
FEMS Immunol Med Microbiol. 2007 Jul;50(2):146-56. doi: 10.1111/j.1574-695X.2007.00237.x. Epub 2007 Apr 18.
Based on the very high prevalence of diseases caused by Helicobacter pylori, particularly in the developing world, and the rapid emergence of antibiotic resistance among clinical isolates, there is a strong rationale for an effective vaccine against H. pylori. In this review we describe recent promising candidate vaccines and prophylactic or therapeutic immunization strategies for use against H. pylori, as well as studies to identify immune responses that are related to protection in experimental animals. We also describe identification of different types of immune responses that may be related to protection against symptoms based on comparisons of H. pylori-infected patients with duodenal ulcers or gastric cancer and asymptomatic carriers. We conclude that there is still a strong need to clarify the main protective immune mechanisms against H. pylori as well as to identify a cocktail of strong protective antigens, or recombinant bacterial strains that express such antigens, that could be administered by a regimen that gives rise to effective immune responses in humans.
鉴于幽门螺杆菌引起的疾病患病率极高,尤其是在发展中世界,而且临床分离株中抗生素耐药性迅速出现,因此有充分的理由研发一种有效的幽门螺杆菌疫苗。在本综述中,我们描述了近期有前景的候选疫苗以及用于对抗幽门螺杆菌的预防性或治疗性免疫策略,还有在实验动物中确定与保护作用相关的免疫反应的研究。我们还描述了基于幽门螺杆菌感染的十二指肠溃疡或胃癌患者与无症状携带者的比较,确定可能与预防症状相关的不同类型免疫反应。我们得出结论,仍然迫切需要阐明针对幽门螺杆菌的主要保护性免疫机制,以及确定一组强大的保护性抗原或表达此类抗原的重组菌株,这些抗原或菌株可以通过一种能在人体中引发有效免疫反应的方案进行给药。